SCMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sucampo Pharmaceuticals's Average Total Inventories for the quarter that ended in Sep. 2017 was $23.6 Mil. Sucampo Pharmaceuticals's Revenue for the three months ended in Sep. 2017 was $61.3 Mil. Sucampo Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2017 was 0.39.
Sucampo Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2017 increased from Jun. 2017 (0.39) to Jun. 2017 (0.39)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory. Sucampo Pharmaceuticals's Days Inventory for the three months ended in Sep. 2017 was 123.70.
Inventory Turnover measures how fast the company turns over its inventory within a year. Sucampo Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2017 was 0.74.
The historical data trend for Sucampo Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sucampo Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | - | - | - | 0.22 | 0.12 |
Sucampo Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.40 | 0.33 | 0.41 | 0.39 | 0.39 |
For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Sucampo Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sucampo Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2016 is calculated as
Inventory-to-Revenue (A: Dec. 2016 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2015 ) | + | Total Inventories (A: Dec. 2016 )) | / | count ) | / | Revenue (A: Dec. 2016 ) |
= | ( (33.121 | + | 23.468) | / | 2 ) | / | 230.056 |
= | 28.2945 | / | 230.056 | ||||
= | 0.12 |
Sucampo Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2017 is calculated as
Inventory-to-Revenue (Q: Sep. 2017 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Jun. 2017 ) | + | Total Inventories (Q: Sep. 2017 )) | / | count ) | / | Revenue (Q: Sep. 2017 ) |
= | ( (23.098 | + | 24.176) | / | 2 ) | / | 61.266 |
= | 23.637 | / | 61.266 | ||||
= | 0.39 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sucampo Pharmaceuticals (NAS:SCMP) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sucampo Pharmaceuticals's Days Inventory for the three months ended in Sep. 2017 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2017 ) | / | Cost of Goods Sold (Q: Sep. 2017 ) | * | Days in Period |
= | 23.637 | / | 17.436 | * | 365 / 4 | |
= | 123.70 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sucampo Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2017 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2017 ) | / | Average Total Inventories (Q: Sep. 2017 ) |
= | 17.436 | / | 23.637 | |
= | 0.74 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Greenleaf | officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Maureen Oconnell | director | |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jones W. Bryan | officer: Sr. Vice Pres., BD & Licensing | C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Peter A Kiener | officer: Chief Science Officer | 40 GUEST STREET, BOSTON MA 02135 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Peter P. Pfreundschuh | officer: CFO | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Paul R Edick | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
Thomas J Knapp | other: Former Officer | 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239 |
William Ashton | director | C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073 |
Timothy I Maudlin | director | 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347 |
Nantahala Capital Management, Llc | 10 percent owner | 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840 |
Mariam E Morris | officer: Chief Acctg. Officer, Treas. | C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814 |
From GuruFocus
By gurufocus 10qk • 05-10-2010
By gurufocus 10qk • 11-03-2010
By gurufocus 10qk • 11-06-2009
By gurufocus • 08-08-2009
By gurufocus 10qk • 03-08-2011
By reports.droy reports.droy • 03-04-2015
By alicet236 alicet236 • 10-21-2013
By gurufocus 10qk • 08-05-2010
By gurufocus • 05-12-2009
By Omar Venerio Omar Venerio • 11-01-2017
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.